Honey Naturals presents kids’ cough syrup at ECRM Cough, Cold and Allergy
SALT LAKE CITY Honey Naturals will be promoting its children’s cough syrup at the ECRM Cough, Cold and Allergy event in Jacksonville, Fla. next week, the company announced Wednesday.
The company’s new product, ZarBee’s Children’s Cough Syrup, is an all-natural, honey-based cough suppressant that provides children relief from coughs while simultaneously boosting the immune system.
“As a pediatrician, I found it extremely frustrating that I was unable to offer any help to my young patients to find relief from their coughs,” stated Zak Zarbock, a practicing pediatrician and developer of the cough syrup.
According to a recent Penn State research trial cited by Honey Naturals, dark honey has been proven to be safer and more effective than Dextromethorphan, the active ingredient in many cough medicines. ZarBee’s Cough Syrup uses a unique blend of dark honey known to be higher in antioxidants than traditional clover honey. The syrup also contains a child’s recommended daily serving of vitamin C and zinc gluconate.
Honey Naturals is looking to expand upon the regional sales success of its ZarBee’s products in the Mountain West and is planning to secure national distribution with one or more retail chains with a nationwide presence.
Perrigo names VP OTC marketing, consumer health care
ALLEGAN, Mich. Perrigo has promoted Ron Schutt to VP OTC marketing, consumer health care.
Schutt has served Perrigo for 15 years, joining the company in 1993 as a marketing analyst and working through roles in international marketing, pharmaceutical business development and consumer healthcare marketing. Most recently, he served as director of marketing for Perrigo’s U.S. over-the-counter drug business where he managed several of the most successful product launches in the company’s history.
Ron Schutt earned his bachelor’s degree in computer information systems from Ferris State University and his master’s in business administration from Western Michigan University.
Pfizer to manage holdings as small units
NEW YORK Drug maker Pfizer will manage its holdings as small units in a similar fashion to Johnson & Johnson, CEO Jeffrey Kindler told Bloomberg.
Kindler told the news agency that following Pfizer’s acquisition of Wyeth, which caused the world’s biggest drug maker to grow by 50%, he is dividing it into separate units to manage various product divisions, which include prescription drugs, OTC drugs, vitamins and vaccines.